ZIA BC 011584 (ZIA) | |||
---|---|---|---|
Title | Clinical trials in women's cancers | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Annunziata, Christina | NCI Program Director | N/A |
Cancer Activity | N/A | Division | CCR |
Funded Amount | $174,715 | Project Dates | 01/01/2013 - 00/00/0000 |
Fiscal Year | 2015 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Cancer (100.0%) Chemotherapy (50.0%) |
Breast (20.0%) Cervical Cancer (5.0%) Ovarian Cancer (70.0%) Uterine (5.0%) |
||
Research Type | |||
Systemic Therapies - Clinical Applications Patient Care and Survivorship Issues |
|||
Abstract | |||
In 2014, I became the Acting Director of the Women's Malignancies Branch. We are currently in the process of analyzing specimens and data from clinical trials 07C0058 - Bevacizumab and Sorafenib phase 2 in ovarian cancer; 08C0092 - Carboplatin and Olaparib in three cohort of patients: BRCA mutation carriers, high-grade serous ovarian cancer, triple negative breast cancer; and 09-C-0191 phase 1 study of bevacizumab and dasatinib. We have submitted for publication the results of clinical trial 12C0191 - SMAC-mimetic birinapant phase 2 in ovarian cancer. We currently have three clinical trials open to patient follow up (11C0022 - Pharmacokinetics of Carboplatin and Olaparib in women's cancers; 09C0019 - Bevacizumab and Dasatinib phase 1 trial; 12C0081 - Olaparib and Cederinib in ovarian cancer phase 1-2 trial). Two of our clinical trials are currently open to accrual: 14-C-0156 CHEK inhibitor for women with Triple Negative Breast Cancer and High Grade Serous Ovarian Cancer. |